Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Expo on Google News
SYS-CON.TV
Cloud Expo & Virtualization 2009 East
PLATINUM SPONSORS:
IBM
Smarter Business Solutions Through Dynamic Infrastructure
IBM
Smarter Insights: How the CIO Becomes a Hero Again
Microsoft
Windows Azure
GOLD SPONSORS:
Appsense
Why VDI?
CA
Maximizing the Business Value of Virtualization in Enterprise and Cloud Computing Environments
ExactTarget
Messaging in the Cloud - Email, SMS and Voice
Freedom OSS
Stairway to the Cloud
Sun
Sun's Incubation Platform: Helping Startups Serve the Enterprise
POWER PANELS:
Cloud Computing & Enterprise IT: Cost & Operational Benefits
How and Why is a Flexible IT Infrastructure the Key To the Future?
Click For 2008 West
Event Webcasts
Omeros Responds to Misleading Announcement by Davis Wright Tremaine Concerning Settlement with Former Chief Financial Officer

SEATTLE, Nov. 9, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today is addressing misleading statements in a press release issued yesterday by Davis Wright Tremaine, the law firm representing Richard J. Klein, Omeros' former chief financial officer with whom Omeros recently settled a lawsuit regarding his employment with Omeros.  Omeros' reasoned decision to enter into the settlement agreement and focus on its business is explained in its Current Report on Form 8-K filed with the Securities and Exchange Commission on November 1, 2012.  The settlement involved the release of all parties' claims, including Mr. Klein's claim to all Davis Wright Tremaine fees incurred since 2009. Omeros' insurance carrier has agreed to advance payment of the settlement funds subject to a reservation of rights.

Mr. Klein's employment with Omeros was terminated in January 2009. In September 2009, five days following Omeros' public filing of its intent to market its initial public offering, Thomas A. Lemly, partner at Davis Wright Tremaine, filed Mr. Klein's initial complaint alleging wrongful termination in retaliation for his whistleblow in connection with a grant awarded to Omeros by the National Institutes of Health (NIH). 

Omeros flatly denies that its termination of Mr. Klein's employment was retaliatory. Omeros believes that it had well-documented good cause to terminate Mr. Klein, including for his performance, as is detailed at length in the public record of this lawsuit.  Further, the evidentiary ruling by U.S. District Judge John C. Coughenour, cited in Davis Wright Tremaine's press release and issued well after the parties had commenced settlement negotiations, was a ruling on the admissibility of circumstantial evidence, which Omeros believed related only to claims that Judge Coughenour had previously dismissed, and not a finding of fact.

During Mr. Klein's employment with Omeros, he used Omeros' Whistleblower Policy procedures to report to the chairman of Omeros' audit committee that the Company had submitted reimbursement claims to the NIH in connection with the grant for work that Omeros had not performed. Omeros' audit committee, with independent outside counsel, thoroughly investigated Mr. Klein's allegations and the Company's NIH grant and claims procedures. The facts gathered by this investigation demonstrate that Omeros underbilled – not overbilled – the NIH in connection with the grant.  In May 2009, Omeros voluntarily reported to the NIH's Office of Compliance the Company's handling of Mr. Klein's whistleblow allegation and the nature of its research under the grant.

Mr. Klein subsequently presented his claims to the U.S. government, which declined to intervene in his case following its investigation of those claims. The written evidence shows that the NIH officials who reviewed Omeros' voluntary report acknowledged in 2009 that the Company had satisfactorily addressed the matter. An NIH scientist charged with managing the grant also testified that the research performed by Omeros represented a very valuable scientific advancement.  In addition, the same NIH institute that awarded the grant that was the subject of Mr. Klein's allegations recently awarded Omeros a new grant in support of the Company's research.

About Omeros Corporation
Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system. The Company's most clinically advanced product candidates are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has four ongoing clinical development programs. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, coagulopathies and central nervous system disorders.

SOURCE Omeros Corporation

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Cloud Developer Stories
The physical world holds the key to unlocking unseen business opportunities that expand revenue, optimize operations and delight customers and users. What if you could turn normally hidden bits of information in your business' physical assets into valuable insights that fuel grow...
SYS-CON Events announced today that Cloudian, Inc., the leading provider of hybrid cloud storage solutions, has been named “Bronze Sponsor” of SYS-CON's 15th International Cloud Expo®, which will take place on November 4–6, 2014, at the Santa Clara Convention Center in Santa Clar...
Recent high profile security breaches at major online websites tell us static passwords are not the answer. Even recent SMS security additions to consumer websites do little to address the issue. Fortunately, a more secure authentication system is available for consumer websites...
The Domain Name Service (DNS) is one of the most important components in networking infrastructure, enabling users and services to access applications by translating URLs (names) into IP addresses (numbers). Because every icon and URL and all embedded content on a website require...
Internet of @ThingsExpo Silicon View billboards on Highway 101 are seen by 1.3 million motorists per week. Internet of @ThingsExpo announces that its Call for Papers is now open. Topics include all aspects of providing or using massively scalable IT-related capabilities as a serv...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021



SYS-CON Featured Whitepapers
ADS BY GOOGLE

Breaking Cloud Computing News
Pericom Semiconductor Corporation (NASDAQ: PSEM), a worldwide supplier of high performance connectiv...